Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 5, 2019

Primary Completion Date

May 29, 2023

Study Completion Date

May 29, 2023

Conditions
Transplantation InfectionCytomegalovirus Infections
Interventions
DRUG

Valganciclovir

"Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."

DRUG

Ganciclovir

"Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."

Trial Locations (7)

14004

Hospital Univesitario Reina Sofía, Córdoba

15006

Hospital Universitario de A Coruña, A Coruña

28041

Hospital Universitario 12 de Octubre, Madrid

28222

Hospital Universitario Puerta de Hierro, Majadahonda

39008

Hospital Universitario Marques de Valdecilla, Santander

46026

Hospital Universitario La Fe, Valencia

08035

Hospital Universitario Vall D'Hebron, Barcelona

All Listed Sponsors
collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

Maimónides Biomedical Research Institute of Córdoba

OTHER